Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
Patient Care
Advances in Targeted Therapy for Breast Cancer
Clinical Topics
-
Is early-onset cancer an emerging global epidemic? -
Cost paramount when choosing metastatic breast cancer treatment -
Genetic tests create treatment opportunities and confusion for breast cancer patients -
Time to cancer diagnoses in U.S. averages 5 months -
Single Institution Retrospective Review of Patterns of Care and Disease Presentation in Female Veterans With Breast Cancer During the COVID-19 Pandemic
Digital Edition
Multimedia
Conference Coverage
-
Multiprong strategy makes clinical trials less White -
CBSM phone app eases anxiety, depression in cancer patients -
T-DXd active in many solid tumors; ‘shift in thinking’ -
Huge underuse of germline testing for cancer patients -
‘Professional grief’ is a daily reality for oncologists -
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology -
‘New standard of care’ for capecitabine hand-foot syndrome -
Less therapy may suit older patients with breast cancer -
New study backs up capecitabine dosing practice in metastatic BC -
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Question 1 of 5
